Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop
暂无分享,去创建一个
G L Finch | M. Tabrizi | L. Kinter | L. Roskos | L. Buckley | K. Benson | J. Leighton | J. McNulty | L Kinter | H. Saber | L A Buckley | K Benson | K Davis-Bruno | M Dempster | P Harlow | H G Haggerty | T Hart | J K Leighton | J McNulty | L Roskos | H Saber | A Stauber | M Tabrizi | G. Finch | T. Hart | H. Haggerty | P. Harlow | K. Davis-Bruno | A. Stauber | M. Dempster
[1] Joy A. Cavagnaro,et al. Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.
[2] W. Pardridge. Drug Targeting to the Brain , 2007, Pharmaceutical Research.
[3] M. Tabrizi,et al. Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.
[4] G. Remuzzi,et al. Cellular responses to protein overload: key event in renal disease progression , 2004, Current opinion in nephrology and hypertension.
[5] G. Shopp,et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[6] Kathryn L Chapman,et al. Preclinical safety testing of monoclonal antibodies: the significance of species relevance , 2007, Nature Reviews Drug Discovery.
[7] P. Bugelski,et al. Myeloma-like cast nephropathy caused by human recombinant soluble CD4 (sCD4) in monkeys. , 1992, The American journal of pathology.
[8] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[9] Liudmila Polonchuk,et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. , 2008, Journal of pharmacological and toxicological methods.
[10] K. Aldape,et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.
[11] N. Simister. Placental transport of immunoglobulin G. , 2003, Vaccine.
[12] R. Rodewald,et al. Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat , 1990, The Journal of cell biology.
[13] M. Tabrizi,et al. Preclinical and clinical safety of monoclonal antibodies. , 2007, Drug discovery today.
[14] W. Schwieterman. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective. , 2006, Drug discovery today.
[15] G. A. Lazar,et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.
[16] R. Ober,et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.
[17] Oprs Alert. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .